SDF-1 restores angiogenesis synergistically with VEGF upon LDL exposure despite CXCR4 internalization and degradation

Cardiovasc Res. 2013 Dec 1;100(3):481-91. doi: 10.1093/cvr/cvt209. Epub 2013 Sep 6.

Abstract

Aims: Angiogenesis is compromised under conditions of hypercholesterolaemia. Since disturbed angiogenesis predisposes to ischaemic injuries, efforts have been made to promote angiogenesis by delivery of growth factors. How stromal cell-derived growth factor (SDF)-1 influences angiogenesis under conditions reflecting hypercholesterolaemia was unknown.

Methods and results: We investigated the effects of SDF-1, administered alone or in combination with vascular endothelial growth factor (VEGF), on angiogenesis using proliferation, transwell migration, and Matrigel-based tube formation assays with human umbilical vein endothelial cells that were exposed to low-density lipoprotein (LDL). We observed that SDF-1 dose-dependently enhanced angiogenesis, but only partly reversed the LDL-mediated suppression of angiogenesis. Reduced abundance of SDF-1's receptor, CXCR4, was noted on the surface of LDL-exposed endothelial cells. In subcellular localization studies combined with pharmacological experiments, we showed that the loss of CXCR4 resulted from its internalization and degradation. SDF-1 synergistically increased angiogenesis when combined with VEGF. As a consequence, angiogenesis was fully restored. SDF-1 reduced oxidized LDL formation and increased the anti-oxidant capacity of endothelial cells, most strongly when administered together with VEGF.

Conclusion: Combination therapies of growth factors, specifically SDF-1 and VEGF, might enhance angiogenesis more successfully than monotherapies under conditions of hypercholesterolaemia.

Keywords: Angiogenesis; Capillary formation; Endothelial cell; Growth factor.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Angiogenesis Inducing Agents / pharmacology*
  • Cell Movement / drug effects
  • Cell Proliferation / drug effects
  • Cells, Cultured
  • Chemokine CXCL12 / pharmacology*
  • Dose-Response Relationship, Drug
  • Drug Synergism
  • Endocytosis*
  • Human Umbilical Vein Endothelial Cells / drug effects*
  • Human Umbilical Vein Endothelial Cells / metabolism
  • Humans
  • Lipoproteins, LDL / metabolism*
  • Neovascularization, Physiologic / drug effects*
  • Receptors, CXCR4 / metabolism*
  • Signal Transduction / drug effects
  • Time Factors
  • Transfection
  • Vascular Endothelial Growth Factor A / pharmacology*

Substances

  • Angiogenesis Inducing Agents
  • CXCL12 protein, human
  • CXCR4 protein, human
  • Chemokine CXCL12
  • Lipoproteins, LDL
  • Receptors, CXCR4
  • VEGFA protein, human
  • Vascular Endothelial Growth Factor A
  • oxidized low density lipoprotein